Active ingredient: Artemether/Lumefantrine 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

Design: Single-dose, two-way crossover in-vivo 

Strength: 20 mg/120 mg (Dose= 4 tablets corresponding to a total dose of 80 mg 
artemether and 480 mg of lumefantrine) 

Subjects: Normal healthy males and non-pregnant females, general population. 

Additional Comments: 1. Females should not be pregnant or lactating, and if applicable, 
should practice abstention or contraception during the study. 2. The tablets should be 
swallowed whole (not crushed). 




________________________________________________________________________ 

 

2. Type of study: Fed 

Design: Single-dose, two-way crossover in-vivo 

Strength: 20 mg/120 mg (Dose= 4 tablets corresponding to a total dose of 80 mg 
artemether and 480 mg of lumefantrine) 

Subjects: Normal healthy males and non-pregnant females, general population. 

Additional Comments: 1. Females should not be pregnant or lactating, and if applicable, 
should practice abstention or contraception during the study. 2. The tablets should be 
swallowed whole (not crushed). 




 ________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Artemether, Dihydroartemisinin (DHA) 
and Lumefantrine 

 

Please submit the metabolite (DHA) data as supportive evidence of comparable therapeutic 
outcome. For the metabolite, the following data should be submitted: individual and mean 
concentrations, individual and mean pharmacokinetic parameters, and geometric means and 
ratios of means for AUC and Cmax. 

 

Bioequivalence based on (90% CI): Artemether and Lumefantrine 

 

Waiver request of in-vivo testing: N/A 

 

Dissolution test method and sampling times: 


Please note that a Dissolution Methods Database is available to the public at the OGD website at 
http://www.fda.gov/cder/ogd/index.htm. Please find the dissolution information for this product 
at this website. Please conduct comparative drug dissolution testing on 12 dosage units each of 
all strengths of the test and reference products. Specifications will be determined upon review of 
the application. 


